Fate Therapeutics Inc (NASDAQ:FATE)
| Market Cap | $107.12M-10.8% |
| Revenue (ttm) | $4.75M-33.4% |
| Net Income | -$124.43M+20.3% |
| EPS | -$1.03+22.0% |
| Shares Out | 116.56M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 3,703,250 |
| Open | $1.01 |
| Previous Close | $1.01 |
| Day's Range | $0.90 - $1.02 |
| 52-Week Range | $0.90 - $3.23 |
| Beta | 2.67 |
| Analysts | Buy |
| Price Target | $6.17(+571.38%) |
| Earnings Date | Feb 25, 2027 |
About FATE
Fate Therapeutics, Inc. is a clinical-stage biopharmaceutical firm dedicated to creating advanced, programmed cellular immunotherapies. These innovative treatments are designed to combat cancer and various immune disorders across the globe. A significant portion of its development pipeline concentrates on NK- and T-cell immuno-oncology programs. Key candidates include FT516, which targets acute myeloid leukemia (AML), B-cell lymphoma, and advanced solid tumors; FT596 for B-cell lymphoma and chronic lymphocytic leukemia; FT538, addressing AML and multiple myeloma; FT576, also focused on multiple myeloma; FT819, aimed at both hematologic malignancies and solid tumors; FT536, another program for solid tumors; and FT500, intended for advanced solid tumors. The company also actively engages in strategic collaborations to advance its research and development. It holds an agreement with Ono Pharmaceutical Co. Ltd. for the joint development and commercialization of two novel, "off-the-shelf" iPSC-derived CAR T-cell therapies. Furthermore, Fate Therapeutics maintains a research collaboration and licensing deal with Juno Therapeutics, Inc., focusing on identifying small molecule modulators that can enhance the therapeutic efficacy of genetically engineered T-cell immunotherapies. A separate collaboration and option agreement exists with Janssen Biotech, Inc. Established in 2007, Fate Therapeutics, Inc. is based in San Diego, California.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
Analyst consensus
2 firms rating FATE in the last 3 months, one vote each. Issuer-paid research is not counted.
Next catalysts
- Feb 25, 2027Earnings report
$FATE stock is featured in our Insider Score Rankings, and Insider Trades datasets.
→ All Stock ListsRecently reported changes in FATE holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by FATE's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
FATE Estimated quarterly lobbying spending
Source: U.S. Senate LDA
FATE Revenue by Segment
| Less: | $32.25M | 58.50% |
| Personnel costs | $9.65M | 17.51% |
| Clinical programs | $7.50M | 13.61% |
| Facilities costs | $4.58M | 8.31% |
| Research activities | $992.00K | 1.80% |
| Change in fair value of stock price appreciation milestones | $151.00K | 0.27% |
As of: Q3 2026 (Sep 30, 2026) · Source: SEC EDGAR (10-Q)
U.S. Patents
New FATE patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to FATE from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in FATE
| VTIVanguard Morningstar Total Stock Market ETF | $5.24M |
| VXFVanguard Extended Market ETF | $2.50M |
| CNCRLoncar Cancer Immunotherapy ETF | $893.63K |
| VHTVanguard Health Care ETF | $596.89K |
| SCHASchwab U.S. Small-Cap ETF | $544.18K |
| IWCiShares Micro-Cap ETF | $353.71K |
Estimated from each fund’s disclosed top holdings × AUM
Bull Case vs Bear Case
AI-generated from FATE’s recent data — informational, not investment advice
What’s Behind the Score
Recent Insider Activity
Frequently Asked Questions
ETFs that hold this stock
| CNCR | Loncar Cancer Immunotherapy ETF | 3.33% |
| JFWD | Jacob Forward ETF | 0.88% |
| QQQS | Invesco NASDAQ Future Gen 200 ETF | 0.38% |
| BUSM | EA Series Trust - EA Bridgeway Ultra-Small Company Market ETF | 0.21% |
| STSB | iShares Factors US Small Blend Style ETF | 0.19% |
| JHMH | John Hancock Multifactor Health Care ETF | 0.10% |
| VHT | Vanguard Health Care ETF | 0.00% |
Weight is the stock’s share of each fund’s holdings.
